Agendia Partners with Illumina to Expand Genomic Testing in Breast Cancer Care
Agendia, Inc., a commercial stage company focused on precision oncology for breast cancer, today announced a multi-year partnership with Illumina, Inc. (NASDAQ: ILMN), to co-develop in vitro diagnostic (IVD) tests for oncology testing. The partnership is intended to advance the use of next-generation sequencing (NGS) for decentralized oncology testing and aligns with Illumina’s approach to IVD partnerships in oncology. Agendia joins Illumina’s growing portfolio of more than 30 IVD partners developing over 40 sequencing-based solutions for cancer prognosis, therapy selection, and other applications.
Illumina and Agendia plan to develop new tests to enhance the care and management of breast cancer patients, utilizing the Illumina MiSeq™Dx sequencing platform to expand the range of gene panels available for solid tumor analysis. The company expects its flagship test, MammaPrint®, which is FDA-cleared and currently offered via Agendia’s central laboratory, will be the first decentralized NGS-based breast cancer recurrence risk test cleared by the FDA.
“This partnership represents a major step in Agendia’s integration of NGS technologies and brings us even closer to our promise of providing crucial genomic information to physicians and their patients to guide care at every single step in a patient’s treatment journey,” said Mark Straley, Chief Executive Officer of Agendia. “We believe our current FDA-cleared, broadly reimbursed MammaPrint test provides the perfect foundation for incorporation with Illumina’s MiSeqDx platform. Together, we plan to expand what is possible in breast cancer care and ensure that the essential insights that come from genomic testing are delivered to patients around the world.”
Illumina’s robust diagnostic NGS product portfolio, including the MiSeq™Dx platform, covers a broad range of clinical applications designed for a variety of clinical lab settings. As NGS testing becomes more integrated in routine patient care, Illumina is committed to providing clinical solutions, through both products and partnerships, that enable the diagnosis and management of human diseases.
Agendia’s proprietary testing solutions empower physicians to more accurately diagnose the disease drivers and predict the progression of a woman’s breast cancer. The company’s scientific approach provides a holistic view of the biology underlying an individual patient’s breast cancer, enabling physicians to personalize treatment. The company believes the decentralized MammaPrint NGS test, developed on the Illumina MiSeq™Dx platform, will enable major clinical hospitals worldwide to offer the clinical utility and benefits of MammaPrint to their physicians and patients in-house. In addition, the MammaPrint NGS test will leverage nearly two decades of clinical evidence drawn from 30 clinical studies featuring over 30,000 patients with breast cancer, as well as a 15-year history of FDA clearance, top tier medical society guideline inclusion, and well-established and unique CPT codes for broad reimbursement.
“We are pleased to partner with Agendia, with its deep expertise in genomic testing in breast cancer, to expand the reach of NGS-based genomic testing in cancer care,” said Joydeep Goswami, Chief Strategy and Corporate Development Officer of Illumina. “We believe enabling in-house clinical testing will strengthen the knowledge of the healthcare network, reduce turnaround times, and ultimately better support more patients with improved guidance on care pathways.”
Agendia is a mission-driven, commercial stage company focused on enabling state-of-the-art decision-making by providing physicians with next-generation diagnostic and information solutions that can be used to help improve outcomes for breast cancer patients worldwide. The company currently offers two commercially-available genomic profiling tests that help surgeons, oncologists and pathologists to personalize treatment for women at critical intervention points throughout their patient journey.
MammaPrint® is a 70-gene prognostic test that, along with other clinicopathologic factors, determines a specific patient’s breast cancer recurrence risk. BluePrint® is an 80-gene molecular subtyping test that identifies the underlying biology of an individual breast cancer to provide information about its behavior, long-term prognosis and potential response to systemic therapy. Together, MammaPrint® and BluePrint® provide a holistic view of an individual patient’s breast cancer, enabling physicians to objectively select the best treatment plan.
For more information on Agendia’s assays and ongoing trials, please visit www.agendia.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Westwicke/ICR Healthcare PR
Westwicke/ICR Healthcare PR
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Q4 Inc. Announces Appointment of Chief Financial Officer9.8.2022 13:00:00 CEST | Press release
Q4 Inc. (TSX: QFOR), a leading capital markets communications platform, today announced the appointment of Donna de Winter as chief financial officer (CFO) effective August 8, 2022. Ms. de Winter has been serving as interim CFO since May 31, 2022. “On behalf of the Q4 Board and the entire Q4 team, we are thrilled to announce that Donna has assumed the role of CFO, after serving in an interim capacity for the last few months,” said Darrell Heaps, CEO. “We are incredibly fortunate to benefit from Donna’s breadth of industry expertise across finance, strategy and operations. Donna has added tremendous value to Q4 over the last few years as Chief Operating Officer, and her lens of operational knowledge along with her strong background as a financial leader of both private and publicly traded companies brings a powerful combination and perspective to the CFO role. We look forward to benefiting from Donna’s deep bench of experience as we pursue our strategic vision and path to profitability.
Aria Systems to Showcase TM Forum Catalyst Solution at Digital Transformation World9.8.2022 13:00:00 CEST | Press release
Aria Systems, the leader in helping enterprises grow subscription and usage-based revenue, today announced the company will be at Digital Transformation World (DTW) in September to present the findings and solution resulting from its involvement in one of TM Forum’s most championed catalyst programs. Aria and its partners have been exploring how an event-driven architecture can enable service providers to build more scalable and flexible IT architecture with lower integration costs, and faster time to market. Catalysts are proof-of-concept projects developed collaboratively by members to solve problems presented by leading global communications service providers (CSPs) and define and propose new industry standards. Together with its partners and CSP champions, Aria will demonstrate how the Open Digital Framework (ODF) can be enhanced for organizations that have adopted a modern event-driven architecture. “As CSPs transform their BSS solution with best-of-breed capabilities to support n
Ferring Announces U.S. FDA Advisory Committee Meeting for RBX2660 its Investigational Microbiota-Based Live Biotherapeutic9.8.2022 13:00:00 CEST | Press release
Ferring Pharmaceuticals today announced that the Vaccines and Related Biological Products Advisory Committee (VRBPAC) of the U.S. Food and Drug Administration (FDA) will hold a meeting on September 22, 2022, to review data supporting the biologics license application (BLA) for RBX2660, a microbiota-based live biotherapeutic studied for its potential to reduce recurrent C. difficile infection (CDI) after antibiotic treatment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220809005214/en/ “The gut microbiome is a highly diverse community of microbes that plays an essential role in human health. Emerging research has shown the promise of leveraging the microbiome to address a range of conditions, including serious diseases such as recurrent C. difficile infection,” said Elizabeth Garner, Chief Scientific Officer, Ferring Pharmaceuticals, U.S. “The cycle of recurrent CDI represents a significant public health burden, and Ferrin
MarineMax To Acquire IGY Marinas Significantly Expanding Global Marina and Services Business9.8.2022 12:45:00 CEST | Press release
MarineMax, Inc. (NYSE: HZO), the world’s largest recreational boat and yacht retailer, today announced that it has entered into a definitive agreement to acquire Island Global Yachting LLC (“IGY Marinas”), which owns and operates a collection of iconic marina assets and a yacht management platform in key global yachting destinations. MarineMax will acquire IGY Marinas for $480 million in cash, with an additional potential earnout of up to $100 million two years after closing, subject to the achievement of defined performance metrics. IGY Marinas, through recent acquisitions and organic growth, is projected to generate over $100 million of revenue in calendar 2022. Subject to the satisfaction of customary closing conditions, MarineMax expects the acquisition to close in the first half of fiscal 2023 and to be accretive within the first twelve months of closing. IGY Marinas will maintain its luxury branding that is well recognized as best-in-class in the global marina and superyacht comm
Everdome Secures US$10 million Investment Commitment from GEM Digital Limited9.8.2022 11:00:00 CEST | Press release
Everdome, the most hyper-realistic metaverse, has announced that GEM Digital Limited (GEM), a Bahamas-based digital asset investment firm that sources, structures and invests in utility tokens listed on over 30 CEXs and DEXs globally, has agreed to an investment commitment of US$10 million into the UAE-based metaverse company through a structured token subscription agreement. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220809005321/en/ Everdome Secures US$10 million Investment Commitment from GEM Digital Limited (Photo: AETOSWire) The announcement comes during a period of heightened activity for Everdome, particularly in terms of its product roll-out and the company’s auction of metaverse land plots. Since June 2022, a total of 11,700 plots (97%) located throughout the Everdome metaverse were sold throughout an eight week auction experience. In total, plots were purchased for upwards of US$18.6 million, which is equivalen
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom